NCT04262635进行中（未招募）3 期
A Phase III, Multicenter, Open-label, Randomized Study to Assess the Efficacy and Safety of Cetuximab Plus Capecitabine Versus Cetuximab as Maintenance Treatment Following First-line Induction Treatment With FOLFOX and Cetuximab in Chinese Patients With RAS and BRAF Wild-type Metastatic Colorectal Cancer
Sun Yat-sen University1 个研究点 分布在 1 个国家目标入组 80 人开始时间: 2021年9月24日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Efficacy: Maintenance PFS
研究概览
简要总结
This is an open-label, multicenter, randomized study to be conducted in Chinese patients with RAS and BRAF wild-type mCRC. Patients who have already completed 9 cycles of standard first-line induction treatment, without discontinuation for toxicity, of cetuximab or fluorouracil or oxaliplatin,, and achieved disease control (including CR/PR and SD), and are progression free at the end of Cycle 9 will be assigned to 2 maintenance treatment groups by randomization in a 1:1 ratio to receive cetuximab + capecitabine (Arm A) or cetuximab alone (Arm B). The randomization will be stratified by induction treatment response (complete response [CR]+ partial response [PR] versus stable disease [SD]) and primary tumor location (left side only versus right side). All patients from Arm A and Arm B will be treated until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal (whichever occurs earlier).
详细描述
Coz COVID-19 limited, C-CLASSIC was terminated recruitment on 31Dec2022. Total screen 100 subjects and enroll 80 subjects. All subjects in study will be treatment until meet study endpoint. Then study related subject follow up, data collect, clinical study report will be continued as planned.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Written informed consent prior to performance of any study procedure.
- •Patient must be ≥18 years of age, at the time of signing the informed consent.
- •Patients who have histologically or cytologically confirmed adenocarcinoma of the colon or rectum, excluding appendix carcinoma or anal canal carcinoma, with RAS and BRAF wild-type mutation status.
- •Patients who received only FOLFOX plus cetuximab as first-line induction treatment after diagnosis of mCRC.
- •Having completed FOLFOX plus cetuximab for 9 cycles as induction treatment (in the first cycle, they could be treated with FOLFOX alone for waiting the results of genetic test) without discontinuation for toxicity, of cetuximab or fluorouracil or oxaliplatin and achieved disease control (including CR/PR and SD) and are progression free at the start of maintenance therapy.
- •At least one lesion(s), which is considered as unresectable at start of maintenance therapy (mCRC patients with resectable lesion(s) after induction treatment can be enrolled if they are willing to choose maintenance therapy). Patients who achieved CR and had no measurable lesion after induction treatment can be enrolled in this study.
- •Eastern Cooperative Oncology Group (ECOG) performance status of 0-
- •Life expectancy of at least 12 weeks in the opinion of the investigator.
- •Laboratory requirements
- •Neutrophils ≥1.5×109/L, platelets ≥75×109/L, and hemoglobin ≥9 g/dL;
- •Total bilirubin ≤1.5×upper limit of normal (ULN); aspartate aminotransferase (AST)/serum glutamic-oxaloacetic transaminase (SGOT) and/or alanine aminotransferase (ALT)/serum glutamic-pyruvic transaminase (SGPT)
- •2.5×ULN (≤5×ULN in case of liver metastases); alkaline phosphatase
- •2.5×ULN (≤5×ULN in case of liver metastases, ≤10×ULN in case of bone metastases); lactate dehydrogenase (LDH) <1500 U/L;
- •Creatinine clearance (calculated according to Cockcroft and Gault) >60 mL/min or serum creatinine ≤1.5×ULN.
排除标准
- •Having received chemotherapy for mCRC other than induction therapy with FOLFOX plus cetuximab, except for adjuvant therapy that has ended >9 months (oxaliplatin- based chemotherapy) or >6 months (oxaliplatin-free chemotherapy), prior to the start of the induction treatment.
- •Other concurrently active malignancies, excluding malignancies that are disease free for more than 5 years or carcinoma-in-situ deemed cured by adequate treatment. Patients who are definitely detected as dMMR/MSI-H at the start of induction therapy.
- •Known brain metastasis or leptomeningeal metastasis. Patients with neurological symptoms should undergo brain computed tomography (CT)/ magnetic resonance imaging (MRI) to exclude metastases.
- •Unresolved toxicity greater than or equal to Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 attributed to any prior therapies (excluding anemia, alopecia, skin pigmentation). Patients with platinum induced neurotoxicity greater than or equal to CTCAE Grade 3 should be excluded.
- •Ascites, pleural effusion or pericardial fluid requiring drainage in last 4 weeks.
- •Intestinal obstruction, major gastrointestinal hemorrhage or other diseases not suitable for maintenance treatment in this study as assessed by the investigator within 2 weeks prior to enrollment.
- •Diabetes and hypertension as assessed by the investigator as not eligible for the subsequent maintenance treatment in this study.
- •Myocardial infarction within the last 12 months, severe/unstable angina, symptoms of class III or IV congestive heart failure per New York Heart Association (NYHA) classification.
- •Previous hypersensitivity to any of the study drugs (cetuximab or capecitabine).
- •Deficiency in dihydropyrimidine dehydrogenase (DPD) as manifested by known medical history of fluorouracil adverse reactions.
- •Known infection with human immunodeficiency virus (HIV), acquired immunodeficiency syndrome (AIDS)-related illness, or active hepatitis B (positive HBsAg and HBV-DNA ≥ 2000 IU/mL or 104 copies/mL) or hepatitis C. Patients with previously confirmed COVID-19 infection, including severe, mild, asymptomatic, and recovered patients.
- •Patients with active autoimmune disorders requiring treatment or history of organ transplantation requiring immunosuppressive therapy.
- •Psychiatric disease that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results.
- •Treatment with any of the following within the specified time frame prior to study drug administration
- •Major surgery within 4 weeks (excluding diagnostic biopsy, the surgical incision should be fully healed prior to study drug administration);
- •Radiotherapy within 4 weeks;
- •Anti-cancer therapy other than protocol-specified induction therapy or participation in other clinical studies within 4 weeks.
- •Anti-tumor traditional Chinese medicine within 2 weeks (such as Cantharidin, Cinobufacini).
- •Pregnant (as determined by serum human chorionic gonadotropin [hCG] test) or lactating female, or female planning to become pregnant during treatment and for 2 months after the end of treatment with cetuximab and 6 months after the end of capecitabine. Woman of childbearing potential (WOCBP) with either positive or no pregnancy test at baseline. WOCBP or sexually active men not willing to use contraception during study and for at least 3 months after completion of cetuximab and 6 months after completion of capecitabine. Postmenopausal women must have been amenorrheic for at least 12 months to be considered of non-childbearing potential.
- •Presence of other serious disease or social circumstances that precludes patient enrollment in the opinion of the investigator.
研究组 & 干预措施
ArmA Cetuximab plus Capecitabine
Experimental
Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W); plus capecitabine in 2-week cycles until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
干预措施: Cetuximab, Capecitabine (Drug)
ArmB Cetuximab
Active Comparator
Maintenance therapy with Cetuximab as intravenous (IV) infusion at the dose of 500 mg/m2, given every 2 weeks (Q2W) until progressive disease, death from any cause, unacceptable toxicity or informed consent withdrawal
干预措施: Cetuximab (Drug)
结局指标
主要结局
Efficacy: Maintenance PFS
时间窗: From Baseline to primary completion date, about 42 months
mPFS from randomization to PD or death from any cause
次要结局
- Number of Participants With Adverse Events During Treatment Period(From Baseline to primary completion date, about 42 months)
- Number of Participants With Clinical Laboratory Abnormalities During Treatment Period(From Baseline to primary completion date, about 42 months)
- Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30 (EORTC QLQ-C30)(From Baseline to primary completion date, about 42 months)
- Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CR29 (EORTC QLQ-CR29)(From Baseline to primary completion date, about 42 months)
- Overall Survival(From Baseline to primary completion date, about 42 months)
研究者
Rui-hua Xu, MD, PhD
Professor
Sun Yat-sen University
研究点 (1)
Loading locations...
相似试验
招募中
3 期
The Efficacy and Safety of Modified XELOX(mXELOX) Plus Cetuximab vs FOLFOX Plus Cetuximab in RAS and BRAF WT mCRC PtsColo-rectal CancerNCT05074966Chinese Academy of Medical Sciences314
招募中
不适用
Chemoradiation Versus Esophagectomy for Locally Advanced Esophageal CancerEsophagus CancerNCT02972372The First Affiliated Hospital of Henan University of Science and Technology196
已完成
1 期
Safety of RAD001 in Chinese Patients With Metastatic Renal Cell CancerMetastatic Renal Cell CarcinomaNCT01152801Novartis Pharmaceuticals64
已完成
3 期
Evaluate Efficacy and Safety of X0002 in Treatment of Knee OsteoarthritisKNEE OSTEOARTHRITISNCT05324163Jiangsu XinChen-Techfields Pharma Co., LTD.180
终止
3 期
Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal CancerMetastatic Colorectal CancerNCT05223673Institut de Recherches Internationales Servier7